Welcome to our dedicated page for Pulmatrix SEC filings (Ticker: PULM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmatrix, Inc. filings document material events for a biopharmaceutical issuer developing inhaled therapeutic candidates through its iSPERSE platform. The record includes Form 8-K disclosures on operating and financial results, corporate updates, clinical or regulatory matters, material agreements, shareholder voting matters, governance actions and capital-structure information.
These filings also capture Regulation FD communications and other event reports tied to Pulmatrix's public-company reporting obligations, including disclosures related to strategic transaction agreements and related governance matters.
Pulmatrix, Inc. filed an amendment to its annual report for the year ended December 31, 2025 to correct the date on its independent auditor’s report, while re-presenting full financial statements.
For 2025, Pulmatrix reported no revenue, compared with $7.806M in 2024. Net loss narrowed to $5.162M from $9.559M, driven mainly by sharply lower research and development and general and administrative expenses after the MannKind facility transaction and wind-down of the Cipla PUR1900 collaboration. Year-end cash, cash equivalents and restricted cash were $4.098M, with total assets of $4.139M and stockholders’ equity of $3.810M.
The company highlights that its future operations are highly dependent on closing its pending merger with Cullgen Inc. Under the agreed exchange ratio, pre-merger Cullgen holders are expected to own about 96.4% of the combined company and pre-merger Pulmatrix holders about 3.6% on a fully diluted basis. Pulmatrix also notes it may pursue asset sales and, if strategic alternatives including the merger are unsuccessful, its board may consider dissolution and liquidation.
Pulmatrix (through Eos SENOLYTIX) disclosed preclinical results for MitoXcel™ geropeptide PTC-2105 showing improved body composition, increased lean mass, reduced fat, better physical function, and prolonged benefits versus GLP-1 comparators in long-term animal studies.
The filing reiterates the Merger Agreement dated March 26, 2026 between Pulmatrix and Eos, with the proposed closing expected in the third quarter of 2026, subject to customary conditions and requisite approvals. The companies state merger-associated financings are expected to support pipeline advancement.
Pulmatrix, Inc. is registering the resale of up to 490,910 shares of Common Stock (including up to 36,364 Dividend Shares) issuable upon conversion of 1,000 Series B Convertible Preferred Shares sold in a private placement.
The Preferred Shares convert at a $2.20 conversion price and carry an 8% per annum dividend payable in Common Stock. The selling stockholder listed is RCM Eos PIPE HOLDINGS, LLC; proceeds from sales will go to the selling stockholder, not the company. The shares covered represent approximately 13% of Common Stock outstanding as of the prospectus; shares outstanding were 3,652,285 as of May 27, 2026.
Pulmatrix, Inc. reported a first-quarter 2026 net loss of $1.2 million, improved from a $1.8 million loss a year earlier, as operating expenses fell to $1.3 million with R&D largely paused and lower general and administrative costs.
Cash and cash equivalents were $3.3 million at March 31, 2026, plus $0.7 million of restricted cash, after raising $1.0 million via Series B Convertible Preferred Stock tied to its planned merger with Eos SENOLYTIX. Management states there is substantial doubt about the company’s ability to continue as a going concern if the Eos merger is not completed and notes the board may consider dissolution and liquidation in that case.
Under the merger terms, Eos stakeholders, including new financing investors, are expected to own about 94% of the combined company on a fully diluted basis, leaving current Pulmatrix stockholders with about 6%, while Pulmatrix’s pipeline of iSPERSE-based inhaled therapeutics remains on hold pending funding or strategic transactions.
Pulmatrix reported a Q1 2026 net loss of $1.2 million, compared with $1.8 million a year earlier, as operating expenses fell to $1.3 million from $1.8 million. Research and development spending was under $0.1 million as all clinical development is on hold while the company seeks to license or monetize its assets.
Cash and cash equivalents were $3.3 million as of March 31, 2026, down from $4.1 million at year-end. Management prepared the financials on a going-concern basis and expects available cash to fund operations at least through the anticipated closing of a proposed merger with Eos SENOLYTIX in the third quarter of 2026.
The company entered into a merger agreement with Eos and raised $1.0 million through a private placement of Series B Convertible Preferred Stock to an Eos affiliate. Existing Pulmatrix common shareholders are expected to own approximately 6% of the combined company, without dilution from the preferred stock.
RCM Eos PIPE HOLDINGS, LLC filed a Schedule 13D disclosing a significant investment in Pulmatrix, Inc. It purchased 1,000 shares of Series B Convertible Preferred Stock for $1,000,000, which are convertible into 405,358 Pulmatrix common shares, equal to 9.99% of the company’s common stock on an as-converted basis.
The preferred shares convert at roughly 454.55 common shares per preferred share at a $2.20 conversion price and carry 8% cumulative dividends payable in stock. This financing is tied to a planned merger in which Eos SENOLYTIX stockholders and related investors are expected to own about 94% of the combined company, leaving existing Pulmatrix stockholders with about 6% on a fully diluted basis.
Pulmatrix, Inc. closed a previously announced private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX, Inc. as part of their planned merger process. The investment generated aggregate gross proceeds of approximately $1 million for Pulmatrix.
The Series B Preferred Stock is convertible into Pulmatrix common stock at a conversion price of $2.20 per share, beginning 90 days after the initial issuance date, and includes customary anti-dilution adjustments. Holders of the Series B Preferred Stock vote together with common stockholders as a single class. Pulmatrix currently intends to use the permitted net proceeds for working capital and other general corporate purposes.
Pulmatrix has signed a definitive agreement to merge with privately held Eos SENOLYTIX, a gerotherapeutics company targeting aging-related mitochondrial dysfunction. Pulmatrix will acquire Eos via a stock-for-stock merger, with Eos becoming a wholly owned subsidiary.
Based on the expected exchange ratio, pre‑Merger Eos stakeholders, including new financing investors and fee shares, are expected to own about 94% of the combined company on a fully diluted basis, while existing Pulmatrix stockholders will own about 6%. The combined entity will be renamed Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker "EOSX" if the transaction closes.
Alongside the Merger, Pulmatrix agreed to a $1 million private placement of Series B Convertible Preferred Stock at a stated value of $1,000 per share, convertible at $2.20 per share and carrying an 8% cumulative dividend payable in stock. These preferred shares vote with common stock and are subject to a 180‑day lock‑up and strong transfer restrictions.
Eos separately arranged an up to $18 million financing through convertible notes and equity, plus an additional planned Series A preferred round, to fund its MitoXcel™ platform and lead candidate PTC‑2105. The Merger and financings remain subject to stockholder approvals, Nasdaq listing approval, Form S‑4 effectiveness and other customary closing conditions.
Pulmatrix, Inc. and Eos SENOLYTIX, Inc. entered a definitive merger agreement under which Pulmatrix will acquire Eos and the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq as EOSX. The transaction includes concurrent private financings totaling $19 million to support advancement of Eos’s MitoXcel™ platform and lead clinical candidate PTC-2105 for sarcopenia and sarcopenic obesity. The boards of both companies unanimously approved the Merger, which is expected to close in mid-2026, subject to customary closing conditions including stockholder approvals and effectiveness of a Form S-4 registration statement. Following closing and payment of placement and advisory fees, pre-Merger Pulmatrix stockholders are expected to own approximately 6% of the combined company and pre-Merger Eos stockholders are expected to own approximately 94%.
Pulmatrix, Inc. announced that Cullgen Inc. has terminated their previously agreed merger and all related transactions under the Merger Agreement. No termination fee will be paid by either party, and each will cover its own costs and expenses associated with the deal.
The merger, originally signed in November 2024 and approved by Pulmatrix stockholders in June 2025, had been awaiting approval from the China Securities Regulatory Commission, which was not obtained before Cullgen’s termination on February 28, 2026. Pulmatrix states that it continues to pursue alternative merger opportunities while highlighting its proprietary iSPERSE™ inhaled drug-delivery technology and clinical assets.